Niclosamide 500 mg, 100 Tablets (1 Pack) — TM Niclochrist

Niclochrist™ 500 (Niclosamide)

Niclochrist™ 500 contains Niclosamide (500 mg per tablet), an FDA-approved oral anthelmintic agent manufactured by Christ Pharma under Indian Pharmacopoeia (IP) standards. In modern drug-repurposing and oncology research, Niclosamide is recognised as a potent multi-targeted signal pathway inhibitor and mitochondrial uncoupler. This listing covers a full box of 100 tablets (10 blisters × 10 tablets) — the standard quantity for extended and multi-arm research protocols.

General Pharmaceutical & Manufacturer Information

• Brand Name: Niclochrist™ 500
• Active Ingredient: Niclosamide IP
• Dosage: 500 mg of Niclosamide per tablet
• Form: Oral tablets
• Package Size: 1 Pack — 100 tablets (10 blisters × 10 tablets)
• Manufacturer: Christ Pharma
• CAS Number: 50-65-7
• Molecular Formula: C13H8Cl2N2O4

Therapeutic & Off-Label Mechanisms in Oncology Research

Niclosamide has demonstrated broad-spectrum preclinical activity against various cancer cell lines by targeting fundamental survival mechanisms:

• Mitochondrial Uncoupling & Oxidative Phosphorylation Blockade: Acts as a protonophore, uncoupling oxidative phosphorylation in tumour mitochondria. This inhibits mitochondrial ATP synthesis, shifts energy metabolism and selectively triggers energetic stress and apoptosis in high-demand cancer cells.
• Inhibition of Cancer Stem Cell (CSC) Signalling: Wnt/β-Catenin: Downregulates Frizzled1 (FZD1) and promotes LRP6 degradation, suppressing Wnt signalling — a driver of cell proliferation and stemness.
• STAT3 Inhibition: Blocks STAT3 phosphorylation and nuclear translocation, disrupting growth signals and microenvironmental survival factors.
• Notch & NF-κB Cascades: Downregulates Notch signalling and NF-κB transcriptional activity, reducing pro-inflammatory and anti-apoptotic gene expression.
• mTORC1 Pathway Suppression: Inhibits mTORC1 signalling directly and indirectly through metabolic stress, limiting aberrant protein translation and tumour growth.
• Overcoming Chemotherapy Resistance: By dampening STAT3, Wnt and P-glycoprotein-mediated survival pathways, Niclosamide sensitises resistant tumour cell lines to standard chemotherapeutic agents in preclinical models.

Scientific Context & References

1. Multi-Targeted Signal Inhibition: Research published in Cancer Research and indexed in PMC highlights Niclosamide’s ability to concurrently inhibit Wnt/β-catenin, STAT3, mTORC1 and NF-κB pathways.
2. Cancer Stem Cell Targeting: Studies in Blood and Oncotarget demonstrate that Niclosamide selectively eradicates leukaemic and solid-tumour stem cells by disrupting intracellular redox balance and key self-renewal pathways.
3. Adjuvant Synergy: Preclinical combination studies indicate synergistic cytotoxicity when Niclosamide is paired with metabolic inhibitors or standard therapies across multiple disease models.

Storage & Handling

• Store in a cool, dry place below 30 °C.
• Protect from direct light and moisture.
• Keep out of reach of children.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.